IO Biotech, Inc.
NASDAQ:IOBT
Overview | Financials
Company Name | IO Biotech, Inc. |
Symbol | IOBT |
Currency | USD |
Price | 0.829 |
Market Cap | 54,615,274 |
Dividend Yield | 0% |
52-week-range | 0.66 - 1.95 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mai-Britt Zocca Ph.D. |
Website | https://www.iobiotech.com |
An error occurred while fetching data.
About IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD